PLATELET-ACTIVATING FACTOR (PAF) IN EXPERIMENTAL AND CLINICAL SEPSIS.
Mathiak, Guenther; Szewczyk, Damian; Abdullah, Fizan; Ovadia, Philip; Rabinovici, Reuven
7(6):391-404, June 1997.
(Format: HTML, PDF)
Despite considerable progress in understanding the pathogenic mechanisms of Gram-negative sepsis, the outcome of septic patients has not significantly improved. There are ample data that support a role for inflammatory mediators in sepsis that act in synergy with infectious agents to initiate and propagate the disease process. One such mediator is the glycerophospholipid platelet-activating factor (PAF). The objective of the present review is to summarize experimental and clinical evidence implicating PAF as a mediator in the pathomechanism of sepsis. This review is timely because many potent and selective PAF antagonists have matured for clinical development and a careful analysis of the data that support or refute the merit of clinical trials with such compounds may be important for both academic and pharmaceutical applications.
(C)1997The Shock Society